More extensive research and different methodological approaches, including different primary antibodies and in vivo muscle biopsies, are required to determine whether TDP-43 pathology in muscle biopsy could become a feasible in vivo biomarker for clinical use in ALS and other proteinopathies. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.